Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.
Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320–5.
Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022;101:485–90.
Nishimura Y, Faigenbaum DC, Pierson SK, et al. Validated international definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96(10):1241–52.
Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–83.
Kawabata H, Fujimoto S, Sakai T, et al. Patient’s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179–88.
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.
Allegra A, Rotondo F, Russo S, et al. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis. 2015;55(3):206–7.
Iwasaki T, Kuragano T, et al. TAFRO syndrome with renal biopsy successfully treated with steroids and cyclosporine: a case report. BMC Nephrol. 2022;23:262.
Watanabe M, Haji Y, Hozumi M, et al. Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report. Mod Rheumatol Case Rep. 2023;7(2):475–9.
Yin X, Liu Y, Zhong C, et al. Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice. Br J Haematol. 2023;203(5):803–6.
Kakutani T, Nunokawa T, Chinen N, et al. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine. 2022;101(48): e32200.
Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv. 2023;7(21):6652–64.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–64.
Sakaki A, Hosoi H, Kosako H, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma. 2022;63(10):2499–502.
Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric castleman disease. Am J Hematol. 2016;91:220–6.
José FF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin DDC, Malheiros DMAC, et al. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine. 2017;96: e6271.
Ozeki T, Tsuji M, Yamamoto J, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7:243–7.
Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258–63.
Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7:162–8.
Nakamori A, Akagaki F, Yamaguchi Y, Arima R, Sugiura T. Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly. Intern Med. 2018;57:1123–9.
Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine. 2017;96: e8216.
Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5:1172–9.
Furuto Y, Hashimoto H, et al. Membranoproliferative glomerulonephritis-like finding for TAFRO syndrome, associated with an anterior mediastinal tumor. Medicine. 2018;97(24):e11057.
Leurs A, Gnemmi V, Terriou L, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol. 2019:10:1489.
Saito H, Tanaka K, Kazama J, et al. Pathological finding of progressive renal involvement in a patient with TAFRO syndrome. CEN case report. 2019;8:239–45.
Nagayama Y, Yamato M, Matsui K, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.
Simeni Njonnou SR, Deuson J, et al. Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Report. 2020;13:e234155.
Zhou Q, Xhang Y, et al. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol. 2020;21(1):499.
Shimada K, Sasaki T, Okabe M, et al. TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med. 2021;2:286–93.
Nakayama Y, Mizuno H, Ubara Y, et al. Adolescent-onset TAFRO syndrome with malignant nephrosclerosis-like lesions. Intern Med. 2023;62:2223–9.
Sato H, Kanno A, Fukukawa K, et al. Case report: acase of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. Front Immunol. 2023;14:1266187.
Naomi S, Takashi Y, Kensuke T, Hiruta H, Tomoaki MA, Ichiro T. A case of tafro syndrome who showed remarkable elevation of presepsin level without an apparent infectious disease. J Jpn Soc Lab Med. 2022;70:29–34.
Yamada M, Sada RM, Kashihara E, Okubo G, Matsushita S, Manabe A, et al. TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report. J Infect Chemother. 2022;28:1008–11.
Hirose H, Suzuki H, Umezawa Y, et al. A case of TAFRO syndrome developed after COVID-19 vaccination. Case Rep Nephrol. 2023;2023:7292895.
Hoffmann C, Wechselberger T, Drexel H, et al. Idiopathic multicentric Castleman disease occurring shortly after mRNA SARS-CoV-2 vaccine. Vaccines. 2022;10(10):1725.
Zhao S, Gao N, Qi H, Chi H, Liu B, He B, et al. Suppressive effects of sunitinib on a TLR activation-induced cytokine storm. Eur J Pharmacol. 2019;854:347–53.
Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, lgyarto BZ, et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479.
Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39:3037–49.
Robichaud J, Côté C, Côté F. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-Astrazeneca) vaccination. CMAJ. 2021;193:E1341–4.
Akiyama H, Kakiuchi S, Rikitake J, Matsuba H, Sekinada D, Kozuki Y, et al. Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine. ID Cases. 2021;25: e01245.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03630-x